SCB-2019
candidate vaccine against COVID-19
Press Enter · cited answer in seconds
0 sources
SCB-2019
Summary
SCB-2019 is a funded product[1]. SCB-2019 draws 12 Wikipedia views per month (funded_product category, ranking #7 of 11).[2]
Key Facts
- SCB-2019's instance of is recorded as funded product[3].
- SCB-2019's instance of is recorded as vaccine type[4].
- SCB-2019's manufacturer is recorded as Clover Biopharmaceuticals Inc.[5].
- SCB-2019's developer is recorded as GSK[6].
- SCB-2019's developer is recorded as Dynavax Technologies (United States)[7].
- SCB-2019's subclass of is recorded as protein subunit vaccine[8].
- SCB-2019's subclass of is recorded as vaccine candidate[9].
- SCB-2019's described by source is recorded as A Phase 1 Study of SCB-2019 for COVID-19 in Healthy Volunteers[10].
- SCB-2019's described by source is recorded as Biomimetic nanovaccines for COVID-19[11].
- SCB-2019's vaccine for is recorded as COVID-19[12].
- SCB-2019's funder is recorded as Coalition for Epidemic Preparedness Innovations[13].
Why It Matters
SCB-2019 draws 12 Wikipedia views per month (funded_product category, ranking #7 of 11).[2] SCB-2019 has Wikipedia articles in 5 language editions, a strong signal of global cultural recognition.[14]